...
首页> 外文期刊>Journal of tissue engineering and regenerative medicine >Differential effect of platelet-rich plasma and fetal calf serum on bone marrow-derived human mesenchymal stromal cells expanded in vitro.
【24h】

Differential effect of platelet-rich plasma and fetal calf serum on bone marrow-derived human mesenchymal stromal cells expanded in vitro.

机译:富血小板血浆和胎牛血清对骨髓来源的人间充质基质细胞体外扩增的差异作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Mesenchymal stromal cells (MSCs) derived from various sources have great potential for use in cell-based therapies. Since the proportion of primary MSCs contained in bone marrow or adipose tissue is low, plastic adherence and in vitro expansion are necessary to expand MSCs prior to clinical application. Human platelet-rich plasma has been introduced as an alternative serum source but functional differences have so far not been described. Here we cultured MSCs derived from human bone marrow in medium supplemented with either 10% fetal calf serum (FCS) or 5% and 10% platelet-rich plasma (PRP) until the first or second passage. Parameters under investigation were cell yield, clonogenicity, phenotype as well as migratory and differentiation potential. In addition, the secretion of SDF-1alpha and the induced migration of CD34(+) haematopoietic stem cells (HSCs) were investigated with regard to the different serum source. The use of PRP resulted in a significantly higher expansion rate and yield at passages 0 and 1. In addition, the level of secreted SDF-1alpha was significantly increased in the supernatant of MSCs cultured with FCS instead of human PRP. Consistent with this, the migration capacity of MSCs cultured with 10% FCS as well as their capability to induce the migration of CD34(+) haematopoietic progenitors in a transwell assay was higher. Our results demonstrate that human PRP can be seen as an alternative serum source to FCS for MSC cultivation. However, the requirements of the specific clinical application must be carefully considered before the respective serum source is selected.
机译:源自各种来源的间充质基质细胞(MSC)在基于细胞的疗法中具有巨大的潜力。由于骨髓或脂肪组织中所含原代MSC的比例低,因此在临床应用之前,必须有塑料粘附和体外扩增才能使MSC扩增。已经引入了富含人血小板的血浆作为替代血清来源,但迄今为止尚未描述功能差异。在这里,我们在补充有10%胎牛血清(FCS)或5%和10%富血小板血浆(PRP)的培养基中培养了源自人骨髓的MSC,直到第一次或第二次通过。研究的参数是细胞产量,克隆形成性,表型以及迁移和分化潜能。此外,针对不同的血清来源,研究了SDF-1alpha的分泌和CD34(+)造血干细胞(HSC)的诱导迁移。使用PRP会导致传代0和1的扩增速率和产量显着提高。此外,在用FCS而非人PRP培养的MSC上清液中,分泌的SDF-1alpha的水平显着增加。与此相一致,在transwell分析中,用10%FCS培养的MSC的迁移能力以及诱导CD34(+)造血祖细胞迁移的能力更高。我们的结果表明,人PRP可被视为MSC培养的FCS的替代血清来源。但是,在选择各自的血清来源之前,必须仔细考虑特定临床应用的要求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号